Glaxosmithkline (Large Cap - High Growth) Share Target 2024, 2025 To 2039
|
GlaxoSmithKline Pharmaceuticals Limited |
|||
|
Price: ₹2,275.95 | ||
| 52 Week Low: ₹1,667.85 52 Week High: ₹3,088.00 |
|||
| Market Capital: 41,625.59 Crore (Largecap) | |||
| Healthcare -> Drug Manufacturers - General | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Glaxosmithkline Share Price Target For 2024
- 1.1.1: Glaxosmithkline Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Glaxosmithkline Share Price Target For 2025
- 1.2.1: Glaxosmithkline Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Glaxosmithkline Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Glaxosmithkline Brief Company Overview
- 4: Glaxosmithkline Financial Performance
- 4.0.1: Is Glaxosmithkline A Good Buy For Long Term?
To predict the Glaxosmithkline's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Glaxosmithkline Share Price Target For 2024
The line chart displays the monthly closing prices of Glaxosmithkline with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Glaxosmithkline shares in 2024, see the table below.
Glaxosmithkline Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 2379.9 (+4.56%) | Price Action: 11 Dec 2024 High |
| 2024 Target 2 | 2346.6 (+3.10%) | Price Action: 10 Dec 2024 High |
| 2024 Target 1 | 2322.05 (+2.02%) | Price Action: 09 Dec 2024 Low |
| Current Price | 2275.95 | Glaxosmithkline's share price as of 20 Dec 2024 |
| Stop Loss 1 | 2270.1 (-0.26%) | Price Action: 18 Dec 2024 Low |
| Stop Loss 2 | 2232.2 (-1.93%) | Fibonacci Retracement Level 98.60% |
| Stop Loss 3 | 2164.49 (-4.90%) | Fibonacci Retracement Level 28.20% |
Short-Term Technical Outlook
Current Technical Position: Glaxosmithkline is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹2363.02 serves as the nearest technical reference point.
Historical Returns: 3-month: -16.88% | 6-month: -13.75% | 1-year: +21.96%
Glaxosmithkline Share Price Target For 2025
The line chart displays the monthly closing prices of Glaxosmithkline with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Glaxosmithkline shares in 2025, see the table below.
Glaxosmithkline Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 3315.86 (+45.69%) | Price Action: Chart |
| 2025 Target 2 | 3254.03 (+42.97%) | Price Action: Chart |
| 2025 Target 1 | 3221.81 (+41.55%) | Fibonacci Extension Level 64.90% |
| Current Price | 2275.95 | Glaxosmithkline's share price as of 20 Dec 2024 |
| Stop Loss 1 | 2055.83 (-9.68%) | Price Action: Feb 2024 Low |
| Stop Loss 2 | 2035.27 (-10.58%) | Price Action: Chart |
| Stop Loss 3 | 1998.64 (-12.19%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Glaxosmithkline is currently trading at 42.8% of its 52-week range (₹1667.85 - ₹3088).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +21.96% | 3-year: +40.22% | 5-year: +57.97%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Glaxosmithkline Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹2,275.95 | ||
| 2024 | ₹2,726.77 | +19.81% | ₹2,789.24 |
| 2025 | ₹3,045.03 | +11.67% | ₹3,090.71 |
| 2026 | ₹2,998.49 | -1.53% | ₹3,091.76 |
| 2027 | ₹3,144.06 | +4.85% | ₹3,394.28 |
| 2028 | ₹3,666.38 | +16.61% | ₹3,721.38 |
| 2029 | ₹3,901.27 | +6.41% | ₹3,999.33 |
| 2030 | ₹4,252.59 | +9.01% | ₹4,316.38 |
| 2031 | ₹4,100.20 | -3.58% | ₹4,301.85 |
| 2032 | ₹4,220.19 | +2.93% | ₹4,604.37 |
| 2033 | ₹4,840.88 | +14.71% | ₹4,913.49 |
| 2034 | ₹5,075.77 | +4.85% | ₹5,209.42 |
| 2035 | ₹5,460.14 | +7.57% | ₹5,542.04 |
| 2036 | ₹5,201.92 | -4.73% | ₹5,511.94 |
| 2037 | ₹5,296.32 | +1.81% | ₹5,814.46 |
| 2038 | ₹6,015.39 | +13.58% | ₹6,116.98 |
| 2039 | ₹6,419.51 | +6.72% | ₹6,515.80 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Glaxosmithkline Brief Company Overview
Company Overview GlaxoSmithKline Pharmaceuticals Limited, headquartered in Mumbai, India, is a leading manufacturer and distributor of pharmaceuticals. Founded in 1924, the company offers a diverse range of products, including: Vaccines and specialty medicines ...
Antibiotics and general medicines Products for infectious diseases, HIV, oncology, and immunology With a strong reputation in the industry, the company is committed to delivering innovative and effective healthcare solutions.Glaxosmithkline Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 41,625.59 Crore | Market valuation of Glaxosmithkline's shares. |
| Revenue (TTM) | 3,560.47 Crore | Total revenue generated by Glaxosmithkline over the past twelve months. |
| Net Income (TTM) | +6,750,309,888.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +30.15% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +18.95% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+5.60% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+16.10% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
0.88 | Company's total debt divided by total shareholder equity. |
| Total Debt | 14.79 Crore | Sum of Glaxosmithkline's current & long-term financial obligations. |
| Total Cash | 2,110.82 Crore | Total amount of liquid funds available to Glaxosmithkline. |
| Beta | 0.18 | Beta is less than 1 indicating that the Glaxosmithkline's price is less volatile than the market. |
Is Glaxosmithkline A Good Buy For Long Term?
GlaxoSmithKline (GSK), a large-cap stock with a market capitalization of ₹41,625.59 crore, shows strong long-term potential. While Q2 2024-25 saw a modest debt of ₹14.79 crore against a substantial cash balance of ₹2,110.82 crore, impressive 5-year (68.17%) and 3-year (54.58%) returns highlight consistent growth. The 18.95% profit margin and positive year-over-year earnings growth (16.1%) further bolster its case. Despite a recent 3-month dip (-11.68%), GSK remains a good buy for long-term investors.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
